282 related articles for article (PubMed ID: 21229380)
21. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation.
Scheiber-Mojdehkar B; Lutzky B; Schaufler R; Sturm B; Goldenberg H
J Am Soc Nephrol; 2004 Jun; 15(6):1648-55. PubMed ID: 15153577
[TBL] [Abstract][Full Text] [Related]
22. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.
Saglam F; Cavdar C; Uysal S; Cavdar Z; Camsari T
Ren Fail; 2007; 29(7):849-54. PubMed ID: 17994454
[TBL] [Abstract][Full Text] [Related]
23. Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease.
Ganguli A; Kohli HS; Khullar M; Lal Gupta K; Jha V; Sakhuja V
Ren Fail; 2009; 31(2):106-10. PubMed ID: 19212906
[TBL] [Abstract][Full Text] [Related]
24. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease.
Erichsen K; Ulvik RJ; Nysaeter G; Johansen J; Ostborg J; Berstad A; Berge RK; Hausken T
Scand J Gastroenterol; 2005 Sep; 40(9):1058-65. PubMed ID: 16165718
[TBL] [Abstract][Full Text] [Related]
25. Intravenous iron supplementation in children on hemodialysis.
Leijn E; Monnens LA; Cornelissen EA
J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice.
Khalil A; Goodhand JR; Wahed M; Yeung J; Ali FR; Rampton DS
Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1029-35. PubMed ID: 21857526
[TBL] [Abstract][Full Text] [Related]
27. Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis.
Rangel EB; Espósito BP; Carneiro FD; Mallet AC; Matos AC; Andreoli MC; Guimarães-Souza NK; Santos BF
Ther Apher Dial; 2010 Apr; 14(2):186-92. PubMed ID: 20438541
[TBL] [Abstract][Full Text] [Related]
28. Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetes.
Van Campenhout A; Van Campenhout C; Lagrou A; Manuel-y-Keenoy B
Biometals; 2008 Apr; 21(2):159-70. PubMed ID: 17585373
[TBL] [Abstract][Full Text] [Related]
29. Alteration of plasma total F2-isoprostanes before and after hemodialysis in end-stage renal disease patients.
Kim KM; Jung BH; Paeng KJ; Kim SW; Chung BC
Prostaglandins Leukot Essent Fatty Acids; 2004 May; 70(5):475-8. PubMed ID: 15062851
[TBL] [Abstract][Full Text] [Related]
30. Common presence of non-transferrin-bound iron among patients with type 2 diabetes.
Lee DH; Liu DY; Jacobs DR; Shin HR; Song K; Lee IK; Kim B; Hider RC
Diabetes Care; 2006 May; 29(5):1090-5. PubMed ID: 16644642
[TBL] [Abstract][Full Text] [Related]
31. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
32. Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection.
Stefánsson BV; Haraldsson B; Nilsson U
Free Radic Biol Med; 2008 Nov; 45(9):1302-7. PubMed ID: 18775775
[TBL] [Abstract][Full Text] [Related]
33. The effect of serum albumin level on iron-induced oxidative stress in chronic renal failure patients.
Sezer MT; Akin H; Demir M; Erturk J; Aydin ZD; Savik E; Tunc N
J Nephrol; 2007; 20(2):196-203. PubMed ID: 17514624
[TBL] [Abstract][Full Text] [Related]
34. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.
Li XY; Chang JP; Su ZW; Li JH; Peng BS; Zhu SL; Cai AJ; Zhang J; Jiang Y
Ther Apher Dial; 2010 Jun; 14(3):308-14. PubMed ID: 20609184
[TBL] [Abstract][Full Text] [Related]
35. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival.
Gupta A; Zhuo J; Zha J; Reddy S; Olp J; Pai A
BMC Nephrol; 2010 Aug; 11():16. PubMed ID: 20716362
[TBL] [Abstract][Full Text] [Related]
36. Iron metabolism in kidney allograft recipients: still a mystery?
Malyszko J; Głowińska I; Malyszko JS; Levin-Iaina N; Koc-Zorawska E; Mysliwiec M
Transplant Proc; 2011 Oct; 43(8):2973-5. PubMed ID: 21996204
[TBL] [Abstract][Full Text] [Related]
37. Does non-transferrin bound iron contribute to transfusion related immune-modulation in preterms?
Stark MJ; Keir AK; Andersen CC
Arch Dis Child Fetal Neonatal Ed; 2013 Sep; 98(5):F424-9. PubMed ID: 23475935
[TBL] [Abstract][Full Text] [Related]
38. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
39. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients.
Gelone DK; Park JM; Lake KD
Pharmacotherapy; 2007 Sep; 27(9):1272-8. PubMed ID: 17723081
[TBL] [Abstract][Full Text] [Related]
40. Use of ascorbate-rich dialysate to attenuate oxidative stress in maintenance hemodialysis patients.
Shi XF; Ding F; Zhu QY; Xue J; Lu FM; Gu Y; Lin ST
Ren Fail; 2005; 27(2):213-9. PubMed ID: 15807188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
